BioNet Provides Update on Recombinant Acellular Pertussis Vaccine at BioJapan 2014

          BioNet Recombinant Pertussis vaccine shows safety and immunogenicity in Phase I/II Clinical Study          BioNet-Asia's CEO, Dr Pham Hong Thai provided today an update on the company lead vaccine program in his presentation at BioJapan 2014. Dr Pham said that the current Phase I/II trial in Thailand showed that the vaccine is safe and immunogenic and full results will soon be published in a peer reviewed journal. BioNet Recombinant Acellular Pertussis vaccine will enter clinical Phase II/III in 2015.          Many licensed acellular pertussis vaccines have been associated to a resurgence of pertussis in developed countries. All these vaccines are inactivated by the use of chemicals which denature Pertussis Toxin, the principal antigen present in acellular vaccines. BioNet’s third-generation Pertussis vaccine is using a genetically-inactivated Pertussis Toxin which overcomes the limitations of the chemically-detoxified acellular vaccines. Hence, BioNet Recombinant Pertussis vaccine could potentially be the solution to the re-emergence of pertussis.